RxDoctor Payments Data

Paul Jensen

Optometrist · Renton, WANPI 1891792370

Payments from drug & device makers

What this record shows

Biotissue Holdings Inc. accounts for 75.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $2,282 and has fallen 96.5% since, to $81 in 2025. Among optometrist clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,999in general payments, 2019–2025

Across 26 payments — averaging $115.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$2K
  • Oyster Point Pharma, Inc.$172
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$131
  • Mallinckrodt Enterprises LLC$125
  • Johnson & Johnson Surgical Vision, Inc.$108
  • Tarsus Pharmaceuticals, Inc.$100
  • plus $91 from 4 others
$19,707in research payments, 2019–2025

Across 4 payments — averaging $4926.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$20K

What the payments were for

  • Travel & lodging$1,47349%
  • Food & beverage$1,52651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,999 in reported general payments places this provider in the 90th percentile of 1,267 optometrist providers in Washington.

See all optometrist providers in Washington

Medicare billing

Part B allowed, 2024
$77,073
Medicare patients
243
Services billed
485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Timolol Maleate14$627
Tobramycin-DexamethasoneTobramycin/Dexamethasone16$619
Dorzolamide Hcl19$471
Latanoprost39$443
Prednisolone Acetate14$381
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat22$282
ErythromycinErythromycin Base14$135

Paid to pharmacies, not to this prescriber.

Other optometrist in Renton

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →